Press Releases

Press Releases

  • December 11, 2017
    Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
  • November 9, 2017
    Aileron Therapeutics Reports Third Quarter 2017 Financial Results
  • November 1, 2017
    Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
  • September 19, 2017
    Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes
  • August 24, 2017
    Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
  • August 10, 2017
    Aileron Therapeutics Reports Second Quarter 2017 Financial Results
  • August 3, 2017
    Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
  • June 28, 2017
    Aileron Therapeutics Announces Pricing of Initial Public Offering
  • June 15, 2017
    Aileron Therapeutics Appoints Donald Dougherty as Senior Vice President and Chief Financial Officer
  • June 3, 2017
    Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924